Abiraterone Mylan Evropska unija - slovenščina - EMA (European Medicines Agency)

abiraterone mylan

mylan ireland limited - abirateron acetat - prostatične neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Skytrofa (previously Lonapegsomatropin Ascendis Pharma) Evropska unija - slovenščina - EMA (European Medicines Agency)

skytrofa (previously lonapegsomatropin ascendis pharma)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hipofize in hipotalamični hormoni in analogi - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Xtandi Evropska unija - slovenščina - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamid - prostatične neoplazme - endokrini terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Cetrotide Evropska unija - slovenščina - EMA (European Medicines Agency)

cetrotide

merck europe b.v. - cetrorelix (as acetate) - ovulation; ovulation induction - hipofize in hipotalamični hormoni in analogi - preprečevanje prezgodnje ovulacije pri bolnikih s kontrolirano jajčasto stimulacijo, čemur sledi oocit-pick-up in tehnike pomožne reprodukcije. v kliničnih preskušanjih, cetrotide je bila uporabljena s človeškimi menopavzi gonadotropin (hmg), vendar omejene izkušnje z rekombinantne follicule stimulirajoči hormon (fsh) predlagal, podobno učinkovitost.

Thyrogen Evropska unija - slovenščina - EMA (European Medicines Agency)

thyrogen

sanofi b.v. - tirotropin alfa - Širokopasemske neoplazme - spodnjega režnja hipofize hormoni in analogi, hipofize in hypothalamic hormoni in analogi - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Kisqali Evropska unija - slovenščina - EMA (European Medicines Agency)

kisqali

novartis europharm limited - ribociklib sukcinat - neoplazme dojke - antineoplastična sredstva - kisqali je primerna za zdravljenje žensk z hormon receptorjev (hr)‑pozitiven, human epidermalna rast factor receptor 2 (her2)‑negativna lokalno napredno ali metastatskega raka dojke, v kombinaciji z zaviralec aromataze ali fulvestrant kot začetno endokrine temelji na zdravljenje, ali pri ženskah, ki jih prejeli v pred endokrine terapija. v pre‑ ali perimenopausal ženske, endokrini terapija je treba v kombinaciji z luteinising hormon sproščujoči hormon (lhrh) agonist.

Abiraterone Accord Evropska unija - slovenščina - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - abirateron acetat - prostatične neoplazme - endokrini terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Sogroya Evropska unija - slovenščina - EMA (European Medicines Agency)

sogroya

novo nordisk a/s - somapacitan - rast - hipofize in hipotalamični hormoni in analogi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Ngenla Evropska unija - slovenščina - EMA (European Medicines Agency)

ngenla

pfizer europe ma eeig - somatrogon - growth and development - hipofiza in hypothalamic hormoni in analogi - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Nubeqa Evropska unija - slovenščina - EMA (European Medicines Agency)

nubeqa

bayer ag - darolutamide - prostatic neoplazem, kastracija-odporne - endokrini terapija - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.